Fluvastatin
Brand names: Lescol, Lescol XL (extended-release)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Primary hypercholesterolaemia and mixed dyslipidaemia (Fredrickson IIa and IIb) | Adults | Adjunctive to diet | FDA Approved |
| Heterozygous familial hypercholesterolaemia (heFH) | Adolescents 10–16 years (post-menarche in girls) | Adjunctive to diet | FDA Approved |
| Secondary prevention — coronary revascularisation risk reduction | Adults with clinically evident CHD | Adjunctive to diet | FDA Approved |
| Slowing progression of coronary atherosclerosis | Adults with CHD | Adjunctive to diet | FDA Approved |
Fluvastatin was the first fully synthetic statin, approved by the FDA in 1993 (IR capsule) and 2000 (XL tablet). It is classified as a low-to-moderate intensity statin in the 2018 AHA/ACC cholesterol guideline: fluvastatin 40 mg BID or 80 mg XL provides moderate-intensity therapy (expected ~30–36% LDL-C reduction based on clinical trial data), while 20–40 mg daily is considered low-intensity (expected ~22–25% LDL-C reduction). A key clinical advantage of fluvastatin is its CYP2C9-predominant metabolism, meaning it largely avoids the CYP3A4 drug interactions that restrict the use of lovastatin and simvastatin. The LIPS trial established its role in secondary prevention after percutaneous coronary intervention.
Post-transplant dyslipidaemia (renal and cardiac transplant): Fluvastatin is sometimes preferred in transplant recipients on cyclosporine because other statins carry more severe CYP3A4 interactions, though fluvastatin exposure is still increased and dose must be capped (Evidence quality: Moderate).
Post-PCI statin initiation in patients intolerant of high-intensity statins: The LIPS trial supports early post-PCI statin therapy; fluvastatin may be used when higher-intensity statins are not tolerated (Evidence quality: Low).
Dosing
Adult Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Primary hyperlipidaemia — LDL-C reduction ≥25% required | 40 mg capsule in evening | 40 mg BID or 80 mg XL once daily | 80 mg/day | XL tablet may be taken at any time of day Do not take two 40 mg capsules at one time; use XL for single 80 mg dose |
| Primary hyperlipidaemia — LDL-C reduction <25% required | 20 mg capsule in evening | 20–40 mg once daily | 80 mg/day | Titrate at 4-week intervals based on lipid response |
| Secondary prevention post-PCI (LIPS protocol) | 40 mg BID (capsule) | 40 mg BID or 80 mg XL | 80 mg/day | Initiate within days of PCI per LIPS trial design LIPS used 40 mg BID; XL 80 mg provides comparable LDL-C lowering despite lower systemic exposure |
| Co-administration with cyclosporine | 20 mg capsule once daily | 20 mg BID (capsule only) | 20 mg BID (capsule) | Do not use XL tablet; hard dose cap (FDA PI) Cyclosporine increases fluvastatin exposure |
| Co-administration with fluconazole | 20 mg capsule once daily | 20 mg BID (capsule only) | 20 mg BID (capsule) | CYP2C9 inhibition increases fluvastatin levels (FDA PI) Do not use XL formulation with fluconazole |
Adolescent Dosing (heFH, ages 10–16 years)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Heterozygous familial hypercholesterolaemia | 20 mg capsule once daily | 20–40 mg BID or 80 mg XL | 80 mg/day | Titrate at 6-week intervals; girls must be at least 1 yr post-menarche LDL-C ≥190 mg/dL or ≥160 mg/dL with positive family hx and ≥2 risk factors |
Unlike lovastatin and simvastatin, fluvastatin XL (80 mg) can be taken at any time of day — not restricted to evening dosing. This is because the extended-release formulation provides sustained drug delivery regardless of timing. The IR capsule (20 or 40 mg) is still recommended in the evening. Food delays absorption of the IR capsule and decreases Cmax by ~50%, but does not meaningfully alter overall LDL-C lowering in clinical practice. Fluvastatin can be taken with or without food (FDA PI).
Pharmacology
Mechanism of Action
Fluvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. By reducing intracellular cholesterol in hepatocytes, fluvastatin stimulates upregulation of cell-surface LDL receptors, thereby increasing clearance of LDL-C from the circulation. As the first fully synthetic statin (a fluorinated indole derivative), fluvastatin is structurally distinct from the fungal-derived statins (lovastatin, simvastatin) and the fermentation-derived pravastatin. Beyond cholesterol lowering, fluvastatin demonstrates antiatherogenic, antithrombotic, and antioxidant properties and can improve endothelial function. Maximum LDL-C reduction is typically achieved by 4 weeks of therapy.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~98% absorbed; Tmax <1 h (IR), ~3 h (XL); bioavailability 24% (IR), 29% (XL) due to first-pass | Can be taken with or without food; high-fat meal increases XL bioavailability ~50% but delays absorption |
| Distribution | Protein binding >98%; Vd 0.35 L/kg; relatively hydrophilic | Binding unaffected by warfarin, salicylic acid, or glyburide at therapeutic concentrations |
| Metabolism | CYP2C9 (75%), CYP3A4 (20%), CYP2C8 (5%); inactive metabolites; also a CYP2C9 inhibitor | Key advantage: CYP3A4 inhibitors (ketoconazole, erythromycin, itraconazole) do NOT significantly affect fluvastatin PK; CYP2C9 inhibitors (fluconazole) DO increase exposure |
| Elimination | t½ <3 h (IR); ~9 h terminal (XL, slow-release kinetics); 95% faeces (60% as metabolites), 5% urine | IR has short half-life (evening dosing preferred); XL prolonged release allows any-time dosing; PK not affected by renal impairment |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | 8.9% (IR) | Most commonly reported; rate higher than placebo (5.6%) in controlled trials |
| Dyspepsia | 7.9% (IR); 3.5% (XL) | Dose-related; lower incidence with extended-release formulation |
| Myalgia | 5.0% (IR); 3.8% (XL) | Rates similar across dose ranges; indistinguishable from placebo in some analyses |
| Diarrhea | 4.9% (IR); 3.3% (XL) | Usually mild and self-limiting |
| Abdominal pain | 4.9% (IR); 3.7% (XL) | Includes upper abdominal pain; placebo rate ~3.8% |
| Nausea | 3.2% (IR); 2.5% (XL) | Usually transient; resolves with continued therapy |
| Insomnia | 2.7% (IR) | Not dose-related; consider evening-to-morning timing switch if persistent |
| Fatigue | 2.6% (IR) | Placebo rate ~1.7%; usually mild |
| Influenza-like symptoms | 5.1% (XL) | Reported more commonly with XL formulation vs IR |
| Sinusitis | 2.6% (XL) | Upper respiratory symptoms more common with XL in controlled trials |
| Transaminase elevation (>3× ULN, persistent) | 0.2–2.7% | Dose-related: 0.2% at 20 mg, 1.5% at 40 mg, 2.7% at 80 mg (divided); 1.9% for XL 80 mg |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Myopathy (CK >10× ULN with symptoms) | <0.1% | Weeks to months | Discontinue immediately; check CK and renal function; no cases of CK >10× ULN in LIPS trial |
| Rhabdomyolysis | Very rare | Variable; risk highest with drug interactions | Emergency care; IV hydration; permanently discontinue; monitor renal function |
| Immune-mediated necrotising myopathy (IMNM) | Very rare (post-marketing) | Months to years; persists after discontinuation | Discontinue; anti-HMG-CoA reductase antibody testing; rheumatology referral |
| Hepatotoxicity (symptomatic liver injury) | Rare | Usually within 12 weeks; 91% of cases by week 12 | Stop fluvastatin; investigate alternative aetiologies; do not rechallenge |
| New-onset diabetes mellitus | Uncommon (class effect) | Months to years | Continue statin (CV benefit outweighs risk per FDA); manage diabetes per guidelines |
| Hypersensitivity reactions (anaphylaxis, angioedema, SJS) | Very rare (post-marketing) | Variable | Discontinue permanently; emergency treatment as needed |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Transaminase elevations | 0.6–0.8% | Most common cause in IR trials; dose-related; majority asymptomatic |
| GI adverse effects | 0.3–0.7% | Abdominal pain, dyspepsia, diarrhea, nausea |
| Fatigue | ~0.2% | Uncommon cause of discontinuation |
Fluvastatin-associated transaminase elevations are dose-related and tend to appear early: 91% of cases with persistent elevations (>3× ULN) occurred within 12 weeks of therapy initiation. In pooled analyses, the incidence was 0.2% at 20 mg/day, 1.5% at 40 mg/day, and 2.7% at 80 mg/day (given as 40 mg BID). The majority of affected patients were asymptomatic. If persistent elevations occur, consider dose reduction or discontinuation. Recheck liver enzymes before initiation and whenever clinically indicated.
Drug Interactions
Fluvastatin is primarily metabolised by CYP2C9, with minor contributions from CYP3A4 and CYP2C8. This means that CYP3A4 inhibitors (erythromycin, ketoconazole, itraconazole) do not significantly affect fluvastatin pharmacokinetics — a major clinical advantage over lovastatin and simvastatin. However, CYP2C9 inhibitors (notably fluconazole) do increase fluvastatin exposure. Fluvastatin itself is a mild CYP2C9 inhibitor and an OATP1B1/1B3 and BCRP substrate.
Because fluvastatin is primarily metabolised by CYP2C9 rather than CYP3A4, it avoids the numerous CYP3A4-mediated drug interactions that limit the use of lovastatin and simvastatin. Erythromycin, ketoconazole, itraconazole, and HIV protease inhibitors have no clinically significant effect on fluvastatin levels. This makes fluvastatin a useful option in patients on complex polypharmacy regimens involving CYP3A4 inhibitors.
Monitoring
- Lipid PanelBaseline, 4–12 weeks, then annually
RoutineFasting lipid profile (Total-C, LDL-C, HDL-C, TG). Maximum LDL-C response expected by 4 weeks at any given dose. - Liver Enzymes (ALT/AST)Before initiation; as clinically indicated
RoutineObtain baseline transaminases before starting therapy. Repeat if symptoms of liver injury develop (fatigue, anorexia, jaundice, dark urine). The majority of persistent elevations appear within 12 weeks. - Creatine Kinase (CK)When clinically indicated
Trigger-basedObtain if patient reports unexplained muscle pain, tenderness, or weakness. Consider baseline CK in patients with risk factors for myopathy (elderly, renal impairment, hypothyroidism, interacting drugs). - Fasting Glucose / HbA1cBaseline; periodically in at-risk patients
RoutineStatins may increase HbA1c and fasting glucose. Monitor for new-onset diabetes in patients with metabolic risk factors. - PT/INR (if on warfarin)When fluvastatin started, stopped, or dose changed
Trigger-basedFluvastatin is a mild CYP2C9 inhibitor; may modestly increase warfarin effect. Monitor closely during dose transitions. - Phenytoin LevelsWhen fluvastatin initiated or dose changed
Trigger-basedPhenytoin is a CYP2C9 substrate with narrow therapeutic index. Check phenytoin trough levels when adding or adjusting fluvastatin.
Contraindications & Cautions
Absolute Contraindications
- Active liver disease or unexplained persistent transaminase elevations
- Pregnancy — may cause fetal harm; discontinue immediately if pregnancy recognised
- Breastfeeding — fluvastatin excreted in animal milk; potential for serious adverse effects in nursing infants
- Hypersensitivity to fluvastatin or any excipient (post-marketing reports of anaphylaxis, angioedema, and Stevens-Johnson syndrome)
Relative Contraindications (Specialist Input Recommended)
- Hepatic cirrhosis — AUC and Cmax increase ~2.5-fold; use only with close monitoring and at reduced dose
- Concomitant cyclosporine or fluconazole at doses exceeding 20 mg BID — increased exposure requires specialist risk-benefit assessment
- History of statin-associated myopathy or IMNM — may recur; consider non-statin alternatives
Use with Caution
- Elderly patients (>65 years) — predisposing factor for myopathy; age alone does not alter PK, but comorbidities increase risk
- Uncontrolled hypothyroidism — correct before starting therapy
- Severe renal impairment — not studied at doses >40 mg; use caution at higher doses
- Heavy alcohol use or history of liver disease — monitor closely
- Patients undergoing major surgery or with conditions predisposing to rhabdomyolysis (sepsis, hypotension, trauma, uncontrolled seizures) — consider temporary discontinuation
All statins carry the risk of myopathy, defined as muscle pain or weakness with CK >10× ULN. In rare cases, rhabdomyolysis with myoglobinuria and acute renal failure can occur, which may be fatal. Risk factors include advanced age (>65), renal impairment, uncontrolled hypothyroidism, and concomitant use of certain interacting drugs. Patients should be advised to report unexplained muscle symptoms promptly. For fluvastatin, the specific dose caps with cyclosporine and fluconazole (max 20 mg BID capsule) must be observed.
Patient Counselling
Purpose of Therapy
Fluvastatin helps lower cholesterol levels in the blood, which reduces the build-up of fatty deposits in blood vessel walls and lowers the risk of heart attack, stroke, and the need for procedures to open blocked arteries. It works best when combined with a heart-healthy diet, regular physical activity, and weight management. The medication must be taken long-term to maintain its benefits.
How to Take
Fluvastatin capsules (20 or 40 mg) should be taken in the evening. The extended-release tablet (80 mg) can be taken at any time of day, with or without food. Swallow the XL tablet whole — do not crush, chew, or break it. Do not open capsules. Do not take two 40 mg capsules at the same time; if your prescriber wants you to take 80 mg daily, use the XL tablet or take one 40 mg capsule in the evening and one in the morning.
Sources
- LESCOL/LESCOL XL (fluvastatin sodium) — Full Prescribing Information. Novartis Pharmaceuticals Corporation. Revised 02/2012. FDA DailyMedPrimary reference for indications, dosing, pharmacokinetics, drug interactions, and adverse reactions from placebo-controlled trials.
- LESCOL XL (fluvastatin sodium) — Prescribing Information. Updated 2023. FDA DailyMedMost recent label update including revised pregnancy/lactation language and IMNM warning.
- Fluvastatin Capsules USP — Prescribing Information. Teva Pharmaceuticals. DailyMedGeneric fluvastatin capsule label with updated adverse reactions and IMNM post-marketing data.
- Serruys PWJC, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial (LIPS). JAMA. 2002;287(24):3215-3222. doi:10.1001/jama.287.24.3215Landmark 1677-patient LIPS trial demonstrating 22% relative risk reduction in MACE with fluvastatin 80 mg/day post-PCI over median 3.9 years.
- Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (LCAS). Am J Cardiol. 1997;80(3):278-286. doi:10.1016/S0002-9149(97)00346-9Lipoprotein and Coronary Atherosclerosis Study showing fluvastatin slowed progression and increased regression of coronary lesions.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003Current US cholesterol guideline classifying fluvastatin 40 mg BID / 80 mg XL as moderate-intensity and lower doses as low-intensity.
- Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e52-e81. doi:10.1161/ATV.0000000000000073Comprehensive AHA review of statin safety including myopathy risk factors and hepatic/diabetogenic effects relevant to all statins.
- Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40(4):263-281. doi:10.2165/00003088-200140040-00003Definitive PK review detailing CYP2C9-predominant metabolism, drug interaction profile, and the CYP3A4 independence of fluvastatin.
- Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50(3):209-215. doi:10.1007/s002280050094In vitro study demonstrating fluvastatin’s inhibitory effects on CYP2C9 and relative sparing of CYP3A4.
- Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol. 1992;32(7):630-638. PMID: 1640002Primary PK study establishing fluvastatin’s half-life, bioavailability, and dose-proportional pharmacokinetics in healthy subjects.
- Niemi M, Pasanen MK, Neuvonen PJ. Enantiospecific pharmacogenomics of fluvastatin. Clin Pharmacol Ther. 2019;106(3):668-680. doi:10.1002/cpt.1466Pharmacogenomic study showing CYP2C9*3 markedly increases fluvastatin exposure and SLCO1B1 has enantiospecific effects.
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NIDDK. Fluvastatin. NCBI BookshelfNIH resource on fluvastatin hepatotoxicity patterns, dose-dependent transaminase elevations, and rare clinical liver injury.
- Hirota T, Ieiri I. Drug-drug interactions that interfere with statin metabolism. Expert Opin Drug Metab Toxicol. 2015;11(9):1435-1447. doi:10.1517/17425255.2015.1064890Review of statin metabolic pathways and transporter-mediated interactions, highlighting fluvastatin’s CYP2C9 dependence.